ABSTRACT
Innervation of the hypothalamic median eminence by Gonadotropin-Releasing Hormone (GnRH) neurons is vital to ensure puberty onset and successful reproduction. However, the molecular and cellular mechanisms underlying median eminence development and pubertal timing are incompletely understood. Here we show that Semaphorin-6A is strongly expressed by median eminence-resident oligodendrocytes positioned adjacent to GnRH neuron projections and fenestrated capillaries, and that Semaphorin-6A is required for GnRH neuron innervation and puberty onset. In vitro and in vivo experiments reveal an unexpected function for Semaphorin-6A, via its receptor Plexin-A2, in the control of median eminence vascular permeability to maintain neuroendocrine homeostasis. To support the significance of these findings in humans, we identify patients with delayed puberty carrying a novel pathogenic variant of SEMA6A. In all, our data reveal an undescribed role for Semaphorin-6A in regulating GnRH neuron patterning by tuning the median eminence vascular barrier and thereby controlling puberty onset.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work received support from: the Italian Ministry of Health (GR-2016-02362389) and the Italian Fondazione Telethon (GMR22T1054) to A.C.; the Netherlands Organization for Scientific Research (ENW-VICI) to R.J.P; the National Institute for Health Research (CL-2017-19-002), Wellcome Trust (222049/Z/20/Z), Barts Charity [MGU0552] and the Rosetrees Trust [M222-F1] to S.R.H.; Fondazione Cariplo (2018-0298) and the Fondazione Italiana per la Ricerca sul Cancro (AIRC, 22905) to A.F.. A.L. was partially supported by Fondazione Veronesi and R.O by Fondazione Collegio Ghislieri and Fondazione Telethon.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human embryonic material was provided by The MRC-Wellcome Trust Human Developmental Biology Resource (HDBR, http://hdbr.org) that has ethical approval to collect and distribute embryonic and fetal material to individual researchers, upon project approval (number 200343). The human study protocol was approved by the Ethics Committee for Pediatrics, Adolescent Medicine and Psychiatry, Hospital District of Helsinki and Uusimaa (570/E7/2003). Ethical approval for human studies was granted by the UK London-Chelsea NRES committee (13/LO/0257). All participants provided written informed consent prior to study participation. The study was conducted in accordance with the guidelines of The Declaration of Helsinki. Participants did not receive compensation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵$ These authors jointly supervised this work
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.